The BIO token gives holders early access to top biotech DAOs and tokenized intellectual property.
Vote on topics like IP tokenization, data-sharing policies and allocation of IP licensing and acquisition proceeds.
Drive funding and liquidity to life and world-saving science.
Guide the commercialization of bleeding-edge products and services.
Dr. Ralf Paus's study tests whether FDA-approved, topically-applied T3 and T4 promote the production of key growth factors, metabolism, and stem cell activities on human scalp skin to treat androgenic alopecia.
Funded by HairDAO
Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to
Funded by VitaDAO
The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.
Funded by VitaDAO
Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.
Funded by VitaDAO
Rodrigo Ladesma-Amaro project's objective is to develop innovative bioprocesses for microbial lipid production, integrating genetic and metabolic engineering with bioreactor and downstream optimization.
Funded by ValleyDAO
Jonathan An’s lab proposes to test a series of compounds targeting inflammation in a mouse model of age-related periodontitis, with the goal of finding a geroscience-based treatment for this neglected disease that has a impact on humans
Funded by VitaDAO
Dr. Mario D. Cordero's project aims to investigate the role of the cGAS-STING pathway and cellular senescence in ovarian aging, with a focus on developing treatments to prevent ovarian reserve loss during aging.
Funded by AthenaDAO
Autophagy becomes dysregulated with age and is associated with numerous diseases. The Korolchuk lab, based at Newcastle University, will screen a compound library to identify novel autophagy-activating compounds.
Funded by VitaDAO
Dr. Ralf Paus's study tests whether FDA-approved, topically-applied T3 and T4 promote the production of key growth factors, metabolism, and stem cell activities on human scalp skin to treat androgenic alopecia.
Funded by HairDAO
Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to
Funded by VitaDAO
The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.
Funded by VitaDAO
Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.
Funded by VitaDAO
Rodrigo Ladesma-Amaro project's objective is to develop innovative bioprocesses for microbial lipid production, integrating genetic and metabolic engineering with bioreactor and downstream optimization.
Funded by ValleyDAO
Jonathan An’s lab proposes to test a series of compounds targeting inflammation in a mouse model of age-related periodontitis, with the goal of finding a geroscience-based treatment for this neglected disease that has a impact on humans
Funded by VitaDAO
Dr. Mario D. Cordero's project aims to investigate the role of the cGAS-STING pathway and cellular senescence in ovarian aging, with a focus on developing treatments to prevent ovarian reserve loss during aging.
Funded by AthenaDAO
Autophagy becomes dysregulated with age and is associated with numerous diseases. The Korolchuk lab, based at Newcastle University, will screen a compound library to identify novel autophagy-activating compounds.
Funded by VitaDAO
Experience the success of onchain IP in the BIO ecosystem
The BIO Launchpad makes BioDAO
curation, formation and funding
accessible, open and fun.
BIO token holders gain voting power in a wide range of biotech DAOs and IP assets.
We are scientists, patients, crypto natives, founders and engineers dedicated to accelerating science.
All the details you need to know about BIO
BIO is a protocol for directing capital and talent to biotech DAOs ("BioDAOs”) and tokenized scientific IP. The protocol serves as a decentralized funding, governance and liquidity engine for early-stage science, supercharging preclinical research through globally-sourced liquidity and talent.
What Uniswap did for long-tail crypto projects, BIO aims to do for tokenized science.
BioDAOs are community-owned IP creation engines, focused on a specific biotech area. They bring together scientists, patients, backers and enthusiasts around specific therapeutic areas, such as women's health or neurodegeneration. The R&D and IP generated is monetized by minting IP-NFTs and IPTs, spinning out companies, and licensing/selling the IP to traditional biotech companies. Proceeds flow back to the BioDAO treasuries, to fund and translate the next generation of R&D, further advancing the BioDAO’s mission.
IP-NFTs and IPTs digitize scientific intellectual property (IP) by encoding the associated legal agreements and R&D data on a blockchain. IP Tokens (IPTs) are unique ERC-20 tokens that serve as governance tokens over the scientific IP generated, data-sharing policies and IP licensing and acquisition proceeds.BioDAOs typically hold portfolios of IP-NFTs and IPTs, which they help launch and incubate through tokenization, liquidity and governance.
BIO is the native governance token of the BIO protocol. BIO may be used by holders to signal which bioDAOs to support, vote on future BIO incentives("Bio/acc Rewards"), and vote on programs for the development of bioDAOs and specific IP assets in the BIO ecosystem.
While the BIO token is live, it is not currently transferrable and can only be bought or sold once governance votes to make the token transferrable. This vote is expected by early Q1, 2025.
